Retatrutide Phase 2 Trial Results: What the 24.2% Study Showed

The retatrutide phase 2 trial is the single study behind almost every headline about this compound. Its results, published in the New England Journal of Medicine in 2023, showed the largest average weight reduction recorded in an obesity drug trial to date. This is our plain English analysis of what that study measured, what the numbers mean, and just as importantly what a phase 2 result cannot tell you. For the underlying data, read the original paper at the link above. Retatrutide is not an authorised medicine in the UK, and everything we sell is supplied for laboratory and research use only.

What the Retatrutide Phase 2 Trial Set Out to Test

Phase 2 sits in the middle of drug development. Phase 1 asks whether a compound is tolerable in humans at all. Phase 3 asks whether it works across large populations against real clinical endpoints. Phase 2 sits between them, answering a narrower question: does this compound produce a measurable effect, and at roughly what amount? The retatrutide phase 2 trial was built to find the dose response relationship in adults with obesity, and to check that the triple receptor mechanism behaved in people the way earlier work suggested.

That framing matters because it sets the boundaries of what the study can honestly claim. It was designed to find a signal and a range, not to prove long term safety or to compare retatrutide head to head against the licensed injections people most want to compare it with.

How the Trial Was Designed

The study ran for 48 weeks as a randomised, double blind, placebo controlled trial. Participants were adults with obesity, or with overweight plus at least one weight related condition, assigned to placebo or to one of several target weekly amounts. Every active group escalated gradually from a low starting amount rather than beginning at its target, a design choice that turned out to matter enormously for tolerability. Neither participants nor investigators knew who received what, which is what makes the placebo comparison meaningful.

The Headline Result: 24.2 Percent

At the highest weekly amount, participants lost an average of 24.2 percent of their body weight over 48 weeks. For someone starting at 110kg, that is roughly 26kg. The placebo group lost around 2 percent, which is the normal effect of taking part in a trial with regular monitoring and dietary attention.

Context is what makes that figure striking. Semaglutide trials produced roughly 15 percent and tirzepatide roughly 21 percent, the latter over a longer 72 week period. The retatrutide phase 2 trial reached a higher figure in less time, and the weight curve had not clearly flattened when the study ended, suggesting more reduction might have followed with longer treatment. That last detail is frequently quoted as though it were a finding. It is not. It is an observation about an unfinished curve.

The Dose Response Curve

The relationship between amount and effect was clear but not linear, which is one of the most practically useful outputs of the whole study:

Read the right hand column and the shape becomes obvious. Most of the effect arrives by 4mg, and the final step from 8mg to 12mg buys about two percentage points while side effect rates keep climbing. That plateau is why the Phase 3 programme concentrated its arms in the 8mg to 12mg band rather than pushing higher, and it is the most useful thing the retatrutide phase 2 trial taught anyone modelling protocols. Full schedules sit in our retatrutide dosage guide.

What Changed Beyond Body Weight

• Waist circumference fell alongside weight, indicating the reduction was not purely fluid.
• Blood pressure improved on average across active groups.
• Lipid measures including triglycerides moved favourably.
• Glycaemic markers improved, consistent with the separate diabetes programme.
• Liver fat reduced substantially in participants with elevated levels at baseline, one of the more interesting secondary findings.

These were secondary endpoints, which means the study was not powered to prove them definitively. They point in a consistent direction, but a secondary endpoint is a lead to follow rather than a conclusion to bank.

What the Safety Data Showed

Gastrointestinal effects dominated, as they do across this entire drug class. Nausea, diarrhoea, vomiting and constipation clustered around the escalation steps and eased as participants settled at a stable amount. Rates scaled with amount, reaching roughly 70 percent reporting any such event in the top group against roughly 31 percent on placebo. Discontinuation because of adverse events ran from about 7 percent at mid amounts to about 16 percent at the highest.

The finding unique to this compound was a transient increase in resting heart rate, averaging several beats per minute, peaking around week 24 and declining afterwards. It is attributed to the glucagon receptor activity the dual and single agonists lack. No corresponding rise in serious cardiac events appeared within the study window, but a 48 week trial of this size cannot rule one out, which is precisely why Phase 3 tracks cardiovascular outcomes at scale. Our side effects breakdown covers the full profile.

The Limits of a Phase 2 Trial

Honest reading of the retatrutide phase 2 trial means naming what it cannot support. The sample was a few hundred people, not thousands. The duration was 48 weeks, so nothing is known about years of exposure. There was no active comparator arm, so every comparison with tirzepatide or semaglutide is inference across separate studies rather than direct evidence. Participants received structured support and monitoring that nobody outside a trial gets. And nothing was measured about what happens when treatment stops, which for this class of compound is a genuinely open question.

None of that diminishes the result. It means a phase 2 outcome is a strong signal rather than a settled conclusion, and anyone quoting 24.2 percent as a promise is misrepresenting the study.

What Phase 3 Is Testing Now

The Phase 3 TRIUMPH programme picked up where this study left off, testing longer durations, larger populations, cardiovascular outcomes and specific groups including people with knee osteoarthritis and obstructive sleep apnoea. Those arms, not the phase 2 result, will determine whether any regulator licenses the compound. A submission is expected once they report, with a UK decision from the MHRA unlikely before 2027 and NHS availability later again.

What This Means for the UK

For UK readers the practical position is unchanged by any of this. Retatrutide holds no marketing authorisation, so it cannot lawfully be sold for human use, and the only human use route is a registered clinical trial. Research suppliers, including us, sell it strictly for laboratory work under research use labelling. For the licensed options that already exist, see our comparison with Mounjaro, and the how to get guide sets out every legal route in detail.

Why the Retatrutide Phase 2 Trial Still Dominates the Conversation

Three years on, the retatrutide phase 2 trial is still the study everyone cites, and that says something about how rare its result was. Obesity pharmacology spent decades producing single digit percentage reductions. Crossing 20 percent moved the field into territory previously reserved for bariatric surgery comparisons, and doing it with a weekly injection changed what people considered realistic. That is why a mid stage study of a few hundred participants generated years of coverage.

It is also why so much misinformation attaches to it. Marketing pages quote the retatrutide phase 2 trial headline while omitting the escalation schedule, the side effect rates and the absence of any licence. Reading the study properly is the best defence against every exaggerated claim made in its name.

How to Read Any Trial Result Like This

• Check the comparator. Placebo controlled tells you the effect is real; it does not tell you how the compound ranks against alternatives.
• Check the duration. Weight curves and safety signals both behave differently at 48 weeks than at three years.
• Check whether the endpoint was primary. Secondary findings are leads, not proof.
• Check the dropout rate. A strong average among people who finished can hide a large group who could not tolerate treatment.
• Check the phase. A phase 2 result is a signal to investigate, which is exactly what the retatrutide phase 2 trial triggered.

Apply those five tests to any headline about this compound and the picture stays accurate. Our what is retatrutide explainer covers the mechanism behind the numbers, and the buy retatrutide UK guide covers the legal reality that no trial result changes.

Where the Retatrutide Phase 2 Trial Sits in the Timeline

Development ran in a straight line. Early safety work cleared the compound for wider testing without the dose limiting problems that end many peptide programmes. The retatrutide phase 2 trial then reported in 2023 and became the moment public interest exploded. Phase 3 enrolment followed across several indications, and those arms are still running today. Anyone reading the retatrutide phase 2 trial as a finish line has the sequence backwards: it was the starting gun for the studies that actually decide licensing.

That distinction explains the gap between public expectation and regulatory reality. The retatrutide phase 2 trial made the compound famous, but fame and authorisation are unrelated processes, and only the second one determines what a UK pharmacy can lawfully hand anyone.

Retatrutide Phase 2 Trial FAQ